Skip to content
Screener

Theravance Biopharma TBPH Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$17.7MMiss by $84.3K
EPS-$0.10Miss by $0.12
Revenue estimate$17.8M
EPS estimate$0.03

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$22.0M
EPS estimate$0.24

Financials

Q1 2026

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$835.73M+89.2%
Enterprise value$588.13M+55.1%
P/E7.3×—
P/S7.6×+0.8×

Profitability

See full
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Segments

By segment

See full
Single Reportable$17.7M+15.0%

FAQ

When did Theravance Biopharma report Q1 2026 earnings?
Theravance Biopharma (TBPH) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Theravance Biopharma's Q1 2026 revenue and EPS?
Theravance Biopharma reported revenue of $17.7M and eps of $-0.10 for Q1 2026.
Did Theravance Biopharma beat estimates in Q1 2026?
Revenue missed the consensus estimate of $17.8M by $84.3K. EPS missed the consensus estimate of $0.03 by $0.12.
How did Theravance Biopharma's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 15.0% from $15.4M a year earlier and eps grew 43.4% from $-0.17.
Where can I find Theravance Biopharma's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-056733) and the 10-Q periodic report (0001104659-26-056760) directly on SEC EDGAR. The filing index links above go to sec.gov.